nyuuzyou/wikis huggingface dataset:
Ivosidenib (Tibsovo)

==General information==
Class/mechanism: IDH1 inhibitor. Ivosidenib inhibits the mutant isocitrate dehydrogenase 1 (IDH1) enzyme at lower drug concentrations than wild-type IDH1. Inhibiting mutant IDH1 enzyme prevents formation of the oncometabolite 2-hydroxyglutarate (2HG) in leukemia cells, causes a reduction in IDH1-expressing tumor cells, and increases percentages of mature myeloid cells.Ivosidenib (Tibsovo) package insert Ivosidenib (Tibsovo) package insert (locally hosted backup)Tibsovo manufacturer's website
==Diseases for which it is established==
*IDH1-mutated AML
*IDH1-mutated MDS
*Cholangiocarcinoma
==Patient drug information==
*Ivosidenib (Tibsovo) package insert
*Ivosidenib (Tibsovo) patient drug information (Chemocare)Ivosidenib (Tibsovo) patient drug information (Chemocare)
==History of changes in FDA indication==
===Acute myeloid leukemia===
* 2018-07-20: Granted approval for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Based on AG120-C-001 r/r)
* 2019-05-02: FDA approval expanded for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. (approval expanded to first-line setting with limitations; based on AG120-C-001 untreated)
* 2022-05-25: Approved in combination with azacitidine for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Based on AGILE)
===Cholangiocarcinoma===
* 2021-08-25: Approved for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation. (Based on ClarIDHy)
===Myelodysplastic syndrome (MDS)===
*2023-10-24: Approved for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. (Based on AG120-C-001 r/r)
==History of changes in EMA indication==
*2023-05-04: Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.
*2023-05-04: Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.
==Also known as==
*Code name: AG-120
*Brand name: Tibsovo
==References==
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:IDH1 inhibitors
Category:Acute myeloid leukemia medications
Category:Cholangiocarcinoma medications
Category:Myelodysplastic syndrome medications
Category:FDA approved in 2018
Category:EMA approved in 2023
Ixabepilone (Ixempra)

==General information==
Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.Ixabepilone (Ixempra) package insert Ixabepilone (Ixempra) package insert (locally hosted backup)Ixempra manufacturer's site
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Breast cancer
==Patient drug information==
*Ixabepilone (Ixempra) patient drug informationIxabepilone (Ixempra) patient drug information
*Ixabepilone (Ixempra) patient drug information (Chemocare)Ixabepilone (Ixempra) patient drug information (Chemocare)
*Ixabepilone (Ixempra) patient drug information (UpToDate)Ixabepilone (Ixempra) patient drug information (UpToDate)
==History of changes in FDA indication==
*2007-10-16: Initial approval in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. (Based on CA163-046 & CA163-048)
*2007-10-16: Initial approval as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine. (Based on CA163-081)
==Also known as==
*Code name: BMS-247550
*Generic names: azaepothilone B, epothilone B lactam
*Brand name: Ixempra
==References==
Category:Drugs
Category:Intravenous medications
Category:Irritant
Category:Epothilones
Category:Microtubule inhibitors
Category:Breast cancer medications
Category:FDA approved in 2007
Johns Hopkins University Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The mission of the Hematology & Medical Oncology Fellowship Program at Johns Hopkins is to train, inspire, and mentor outstanding leaders in Hematology and Oncology. Our program offers dual or single certification in Hematology or Oncology. Although we are a combined fellowship program, we offer independent tracks in either Hematology or Medical Oncology that provide a unique 12 month training curriculum that is tailored to each specialty."
==Basic information==
Name: Johns Hopkins University Hematology Oncology Fellowship
Fellowship program website: https://www.hopkinsmedicine.org/kimmel-cancer-center/education-training/hematology-medical-oncology-fellowship
ACGME ID: 1552321154
===Leadership===
*Program Director: Kristen Marrone, M.D.
===Fellowship Coordinator===
Ashley Hartley
Phone: 410-955-8838
Email: ahartle5@jhmi.edu
==Application process and requirements==
https://www.hopkinsmedicine.org/kimmel-cancer-center/education-training/hematology-medical-oncology-fellowship/apply
===Process===
*Applications accepted starting on:
*Application deadline:
*Applications submitted through ERAS
===Requirements===
*CV
*Personal Statement
*Three letters of recommendation; one must be from Program Director
*USMLE transcript
*Photograph requested; not required
For IMGs:
*Completion of medical residency
*Completion ECFMG examinations and certification
*Accepts J1 visa. Holders of an H-1 visa are eligible, however, Johns Hopkins does not initiate sponsorship of an H-1 visa
==Statistics==
*Number of fellowship positions available per year: 10 (8 for the medical oncology track and 2 for the hematology track)
*Board certification eligibility upon fellowship completion: (depending on what fellow chooses) Hematology and Oncology, Hematology, or Oncology
*Length of fellowship: 2 to 3 years
==Schedule==
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
*The Johns Hopkins Hospital
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Juvenile myelomonocytic leukemia

Back to Top
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=First-line therapy=
==Azacitidine monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Niemeyer et al. 2021 (AZA-JMML-001)	2015-2017 	Phase 2, fewer than 20 pts (RT)
====Chemotherapy====
*Azacitidine (Vidaza) by the following age- and weight-based criteria:
**Less than 10 kg or younger than 1 year old: 2.5 mg/kg IV over 10 to 40 minutes once per day on days 1 to 7
**10 kg or more and 1 year old or older: 75 mg/m2 IV once per day on days 1 to 7
28-day cycle for 3 to 6 cycles
===References===
# AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02447666
Category:Juvenile myelomonocytic leukemia regimens
Category:Disease-specific pages
Category:Myeloproliferative neoplasms
Category:Pediatric hematologic neoplasms
Kaposi sarcoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main KS page for regimens that include active anticancer treatment.
=All lines of therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Walmsley et al. 1999 	1996-04 to 1997-07 	Phase 3 (C)	Alitretinoin	Lower ORR
Bodsworth et al. 2001 	Not reported 	Phase 3 (C)	Alitretinoin	Lower ORR
Noy et al. 2005 (AMC 013)	1998-2001 	Phase 3 (C)	IM-862 	Seems to have longer TTP
No active antineoplastic treatment.
===References===
#Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B; Panretin Gel North American Study Group. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46. link to original article EuroPMC
#Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R; International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2001;2(2):77-87. link to original article EuroPMC
#AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article EuroPMC
Category:Kaposi sarcoma regimens
Category:Disease-specific pages
Category:Vascular sarcomas
Category:Null regimens
Ketoconazole (Nizoral)

==Diseases for which it is used==
*Prostate cancer
== Patient Drug Information==
*Ketoconazole (Nizoral) Package InsertKetoconazole (Nizoral) Package Insert
==History of changes in EMA indication==
*1980-06-01: EURD
==Also known as==
*Brand name: Nizoral
==References==
Category:Drugs
Category:Oral medications
Category:CYP17 inhibitors
Category:Antifungals
Category:Prostate cancer medications
Category:FDA approved in 1981
Category:EMA approved in 1980
L-glutamine (Endari)

Pharmaceutical grade L-glutamine
==Diseases for which it is used==
*Sickle cell anemia
==History of changes in FDA indication==
*2017-07-07: Approved for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.
==Also known as==
*Brand name: Endari
Category:Drugs
Category:Oral medications
Category:Sickle cell anemia medications
Category:FDA approved in 2017
Lamivudine (Epivir)

==General information==
Class/mechanism: Antiretroviral; Lamivudine is a cytidine analog and can inhibit both types (1 and 2) of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B. 
Route: PO
Extravasation: N/A
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties. Used for prevention of HBV reactivation for HBV carriers.
==Also known as==
*Brand name: Epivir
Category:Drugs
Category:Oral medications
Category:Antivirals
Category:FDA approved in 1995
Lanreotide (Somatuline)

==General information==
Class/mechanism: Octapeptide somatostatin analog which suppresses multiple endocrine, neuroendocrine, exocrine, and paracrine functions. Lanreotide binds with high affinity to somatostatin receptors (SSTR) 2 and 5, with lower binding affinity for SSTR1, SSTR3, and SSTR4. Binding to SSTR2 and SSTR5 is believed to cause growth hormone (GH) inhibition. Lanreotide also results in reduction of IGF-1 (somatomedin C), motilin, gastric inhibitory peptide, pancreatic polypeptide, gastrin, cholecystokinin (CCK), duodenal bicarbonate and amylase concentrations, gastric acidity, gallbladder contractility, bile secretion, glucagon, and prolactin. It also causes transient decreases in post-prandial insulin secretion and nocturnal release of thyroid-stimulating hormone (TSH).Lanreotide (Somatuline) package insert Lanreotide (Somatuline) package insert (locally hosted backup)Somatuline manufacturer's website
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Neuroendocrine tumor
*Pancreatic NET
==Patient drug information==
*Somatuline package insert
*Lanreotide (Somatuline) patient drug information (UpToDate)Lanreotide (Somatuline) patient drug information (UpToDate)
==History of changes in FDA indication==
*2007-08-30: FDA approved for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. 
*2014-12-16: FDA approved for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. (Based on CLARINET)
==History of changes in PMDA indication==
*2017-07-03: New additional indication and a new dosage indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract.
==Also known as==
*Generic names: lanreotide acetate
*Brand names: Ipstyl, Lanreotide Autogel, Somatuline, Somatuline Autogel, Somatuline Depot, Somatuline LA, Somatuline LP, Somatuline PR
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Somatostatin analogs
Category:Neuroendocrine tumor medications
Category:Pancreatic NET medications
Category:FDA approved in 2007
Lanreotide LAR (Somatuline Depot)

==General information==
Class/mechanism: Long-acting dosage form of Lanreotide (Somatuline). 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Neuroendocrine tumor
==History of changes in FDA indication==
*2007-08-30: Initial FDA approval
==History of changes in Health Canada indication==
*2006-07-17: Initial notice of compliance for long-term treatment of patients with acromegaly due to pituitary tumours who have had inadequate response to or cannot be treated with surgery and/or radiotherapy.
*2006-07-17: Initial notice of compliance for relief of symptoms associated with acromegaly.
*2015-09-28: New indication for the treatment of enteropancreatic neuroendocrine tumors in patients with unsectable, locally advanced or metastatic disease.
*2018-02-02: New indication for the treatment of adult patients with carcinoid syndrome.
==Also known as==
*Generic names: lanreotide long-acting release
*Brand names: Somatuline Depot
Category:Drugs
Category:Intramuscular medications
Category:Somatostatin analogs
Category:Neuroendocrine tumor medications
Category:FDA approved in 2007
Category:Health Canada approved in 2006
Lapatinib (Tykerb)

==General information==
Class/mechanism: EGFR/HER2 tyrosine kinase inhibitor; 4-anilinoquinazoline inhibitor of the intracellular tyrosine kinase domains of EGFR (epidermal growth factor receptor/ErbB1) and HER2 (human epidermal growth factor receptor 2/ErbB2), which drive proliferation in certain malignancies.
Lapatinib (Tykerb) package insertLapatinib (Tykerb) package insert (locally hosted backup)Tykerb manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*HER2+ breast cancer
*HER2+ colon cancer
==Patient drug information==
*Lapatinib (Tykerb) patient drug informationLapatinib (Tykerb) patient drug information
*Lapatinib (Tykerb) patient drug information (Chemocare)Lapatinib (Tykerb) patient drug information (Chemocare)
*Lapatinib (Tykerb) patient drug information (UpToDate)Lapatinib (Tykerb) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2007-03-13: Initial approval in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. (Based on EGF100151)
* 2010-01-29: Accelerated approval in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Based on EGF30008)
**2018-12-06: Converted to regular approval.
==History of changes in EMA indication==
* 2008-06-10: Initial marketing authorization as Tyverb.
==History of changes in Health Canada indication==
*2009-05-15: Initial notice of compliance (unclear details)
*2010-09-30: New indication in combination with letrozole for the treatment of post-menopausal patients with hormone receptor positive metastatic breast cancer, whose tumours over express the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy.
==History of changes in PMDA indication==
*2009-04-22: Initial approval for the treatment of inoperable or recurrent breast cancer with HER2 overexpression.
==Also known as==
*Code name: GW-572016
*Brand names: Abnib, Combinib, Du-Kinib, Etibo, Herduo, Herlapsa, Hertab, Lapanix, Lapatem, Lapatip, Tykerb, Tyverb, Tylidys
==References==
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:EGFR inhibitors
Category:ERBB2 inhibitors
Category:Breast cancer medications
Category:Colorectal cancer medications
Category:EMA approved in 2008
Category:FDA approved in 2007
Category:Health Canada approved in 2009
Category:PMDA approved in 2009
Lapuleucel-T (DN24-02)

==General information==
Class/mechanism: Autologous cellular immunotherapy, designed to stimulate a response against HER2/Neu receptor. Autologous peripheral blood mononuclear cells, which include antigen presenting cells (APCs), are obtained via leukapheresis. They are then activated ex vivo with a recombinant fusion protein.NCT01353222DN24-02 manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Also known as==
*Code name: DN24-02
==References==
Category:Cellular therapy
Category:Intravenous medications
Category:Urothelial carcinoma medications (investigational)
Category:Investigational drugs
Large language model pilot

We are conducting a pilot of generative artificial intelligence to create human-readable synopses for some of the most relevant anticancer regimens on HemOnc.org. The goal of this work is to further contextualize the regimen information that is currently primarily in structured format, providing a historical perspective and overview for site users. 
The following is a general overview of our process:
A commercially available large language model (e.g., Open AI's Chat-GPT; Google's Bard) is prompted to generate a synopsis of a given regimen, using citations from the literature. The typical format is “Create a summary of the evolution of XX regimen for treatment of XX. Use citations from the literature to support this”. The page and/or section editor then reviews and substantially edits the summary for clarity, readability, and accuracy. The synopses are reviewed and approved by the Editor-in-Chief or Deputy Editor before posting on the website.
Any synopsis that has been created in this manner will have a footnote with a pointer to this page, along with the date that it was created.
Please note that our general disclaimer applies to all content on HemOnc.org, regardless of its source.
We are seeking your feedback on this pilot! Please fill out our REDCap form or send us an email at contact @ hemonc.org.
This work is supported in part by NCI U24 CA265879.
Category:General reference pages